Immix Biopharma (IMMX)

• Market cap: $68.6M
• 1 day: -5.41%
• 5 days: -4.11%
• 1 month: -8.7%
• 3 months: -15.66%
• 6 months: 28.83%
• Year to date: -4.55%
• 1 year: 16.02%
• 5 years: -42.78%
• 10 years: -42.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Employees: 21

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

5% more funds holding

Funds holding: 22 [Q1] → 23 (+1) [Q2]

4% less capital invested

Capital invested by funds: $4.9M [Q1] → $4.68M (-$220K) [Q2]

2.41% less ownership

Funds ownership: 10.53% [Q1] → 8.11% (-2.41%) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8
• Avg. target: $8
• High target: $8

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns

$8

Buy Maintained

12 Sep 2025